KYY is a known PH supporter . Pharma is a Glic owned thru LTAT.

Qtr result not due yet

Any one attending the AGM today. Any news ?

Profit taking contra players

Contra players profit taking

LTAT is very happy with pharma price but but ....Bstead price at 80 still far far away from their NTA value of 1.95

Bstead { also owned Affin banking group }

From a high of 66+ now { 8/7 } now drop to 50 sen. sharp drop of 25% matter on 8-10 days

Coming Qtr is bad { GENM } for long term play. Need to hold till recovery after post covid blues eased. Most analyst believed 2021 endQtr gaming/ leisure sector can perk up

KYY flushed with $$$ recover all it's previous misadventure at Jaks n Dayang. KYY is a strong glove supporter

Yesterday all banking stocks down. overplayed on moratorium extension

K1 underperforming. Whatever said and done stuck at 40 sen

Yesterday sell down on banking stocks overplayed on moratorium extension rumours

The share price reflect the street view of the co. mangment

Big volume buyer lots park before break but......but price still not moving.sideway trading 41 - 43

Still early { ding ding between bulls & bears .} 4.30 will see the real picture

Analyst are paid to churn out reports. this IB analyst writes only. it's your money when comes to buying { do your homework }

Glove producers { heavy weights } TG, Harta, Super , Kosssan are at their high end { even more pricey than PBB or HLB } but nobody knows how the bubble play out. Secondary healthcare supplier's { swab test kits, face masks, ventilators and PPE have not sky rocketed compared to glove heavy weights. K1 particularly is a laggard hardly moved for the past 1 month

Errata : more expensive than banking stocks

Better move to second tier health care suppliers { ventilators or swab test kits }. Top 6 heavy weights { glove makers } more expensive thank banks. TG, Super, Harta more pricey compared to PBB, HLB or Cimb

Looks like big players switching out from the big 6 glove makers into other segments

Other healthcare supplier's { except K1 } perform much better. look at HLT or LKL

Lack luster counter . Sideway zzzz

Bet on the wrong horse. Horse not running { worst still limping } unlike other glove counters

Hopefully July will see K1 better performance

This K1 hard to play. Never follow trend. up 1 day down the next 2-3 days.need a viagra

The AGM was a tame affair. All 8 resolutions passed. No announcements

US emergency alert after 2 nd wave of infections surged. A record 44,782 new cases reported in a row { setting a single day record } Florida, Georgia, Carolina,Nevada , Texas all hit new high

Today is a bad day for KLSE

Clinical trials are segregated into stage 1,2, 3 ,4 i.e. before submitting IND { investigation New Drug } application to FDA. The process describe it's method of manufacture, quality control, damping etc for release. WHO mentioned the fastest approval during pandemic outbreak needs between 18 -24 months period. Just my 2 sen worth on Clovis 19 vaccine { a vaccine is different from anti bodies treatment }

K1 has lots of news floating around {KKM approval, FDA ventilators, Qtr positive result, Singapore cloud venture & now JV venture } time to buy on rumors

Yup. Not a good day for glove related health care stocks { despite news of worldwide covid 19 infections spike up

Never like TA or TAG { my own view } remember TAG was a spin-off from TA enterprise. Only Tony make $$$.other shareholder & retailers was left holding his still born. TAE has withdrawn it's voluntary takeover offer TAG ( SC has rejected it's application . But Tony has other means to derail the scheme

This round surprisingly very limited retailers used margin financing. Maybe everybody knows cash is King whereas banks are fair weather friends. kYY was pressured by bank margin calls and force to cut loss was a good lesson { never relied on the banks }

KWSP split their portfolios into 3 categories plus outsourcing to IB 's and fund managers { local and foreign } to manage their portfolios. Category 1 - capital growth & gains, Category 2 - dividend play, Category 3 - trading account

Previously this group of IB 's hardly covered glove producers. They go for the big cap counters. Last Dec. TG almost drop from KLCI. They rank 34

K1 Ventilator approved by US FDA administration ( agreement last until Oct 2024 }

K1 secures licence to manufacture ventilators for covid 19 treatment use ( reported by the edge late evening )

Afternoon limit up { if buying momentum continues }

K1 , Hlt, Lkl are the laggards among the glove trend setters. K1 is in a sweet spot. Pretty decent valuations { small cap plus net cash position } lowest price betw Hlt or Lkl . the latter stocks all rocketed towards > 65 mark { whereas K1 is still Zzzzz }

Agreed with MingGoon. Mah sing long term 2-3 years down the road

All gloves counter now sideways after the 2 days of hot run up. Profit taking and punters taking a break plus long week end break

Raya weekend break. retail buyers may stat away

Share Carelpls news and trading ideas only

Agreed with Eagle eye. Reenter Carelpls in the afternoon opportunity comes once every 10 years

Ansell JV with Carelpls opens lot of opportunities and new markets. Ansell is a reputable { established }MNC big in Europe

Most anaylst believed GENM is facing a tough times at this point of pandemic { not saying GENM close shop } unless they lose their casino licence etc price wise they don't expect any quick recovery. GENM or for that matter PBB { Rock solid banking counter } will face many challenges

BFM interview TG { Tan Sri Lim } their orders backlogged is so bloated unable to fulfill . received overseas orders requested by government for assistance . They can only help by sending token sum as and when available. This is happening to all glove manufacturer's { bypassing middlemen } Ansell is a household brand in overseas { careplus is a direct beneficiary of Ansell link }

What's troubling ! Own shareholder { Suntel int } disposing shares . Total app 7 Million plus after MCO lockdown lifted { from April till now } looks bad when own people selling

Without prejudice CPO higher production in 2nd half and demand likely to shrink. Outlook not promising